Is a Surprise Coming for Ultragenyx (RARE) This Earnings Season?
Investors are always looking for stocks that are poised to beat at earnings season and Ultragenyx Pharmaceutical Inc. RARE may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because Ultragenyx is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for RARE in this report.
In fact, the Most Accurate Estimate for the current quarter is currently at a loss of $1.58 per share for RARE, compared to a broader Zacks Consensus Estimate of a loss of $1.60 per share. This suggests that analysts have very recently bumped up their estimates for RARE, giving the stock a Zacks Earnings ESP of +1.32% heading into earnings season.
Ultragenyx Pharmaceutical Inc. Price and EPS Surprise
Ultragenyx Pharmaceutical Inc. price-eps-surprise | Ultragenyx Pharmaceutical Inc. Quote
Why is this Important?
A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).
Given that RARE has a Zacks Rank #2 (Buy) and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Clearly, recent earnings estimate revisions suggest that good things are ahead for Ultragenyx, and that a beat might be in the cards for the upcoming report.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ultragenyx Pharmaceutical Inc. (RARE) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
